Sort   by:  
 Page size 
UnknownMMP2 and MMP9 serum levels are associated with favorable outcome in patients with inflammatory breast cancer treated with bevacizumab-based neoadjuvant chemotherapy in the BEVERLY-2 study.
Not available
S-EPMC4951307 | biostudies-literature
UnknownNivolumab in combination with ipilimumab versus capecitabine as post-operative treatment for triple negative breast cancer patients with residual disease after neoadjuvant chemotherapy: a multicentre, randomized, open-label phase II trial - BREASTIMMUNE-03.
Not available
S-EPMC12702069 | biostudies-literature
UnknownFactors Associated With the Discussion of Fertility Preservation in a Cohort of 1,357 Young Breast Cancer Patients Receiving Chemotherapy.
Not available
S-EPMC8507557 | biostudies-literature
UnknownTrastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trial.
Not available
S-EPMC12705423 | biostudies-literature
UnknownTrastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
Not available
S-EPMC10561652 | biostudies-literature
UnknownAdjuvant ovarian suppression in premenopausal breast cancer.
Not available
S-EPMC4341825 | biostudies-literature
UnknownTailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer.
Not available
S-EPMC6193457 | biostudies-literature
UnknownAdjuvant exemestane with ovarian suppression in premenopausal breast cancer.
Not available
S-EPMC4175521 | biostudies-literature
Sort   by:  
 Page size